Ascendis Pharma A/SASNDNASDAQ
Loading
Year-over-year revenue growth rate
| Period | Value |
|---|---|
| Q4 2025 | 14.77% |
| Q3 2025 | 35.17% |
| Q2 2025 | 56.55% |
| Q1 2025 | -41.95% |
| Q4 2024 | 200.72% |
| Q3 2024 | 60.66% |
| Q2 2024 | -62.46% |
| Q1 2024 | -30.36% |
| Q4 2023 | 186.68% |
| Q3 2023 | 1.35% |
| Q2 2023 | 41.10% |
| Q1 2023 | 46.70% |
| Q4 2022 | 49.74% |
| Q3 2022 | 148.21% |
| Q2 2022 | -9.78% |
| Q1 2022 | 39.43% |
| Q4 2021 | 339.98% |
| Q3 2021 | 8.90% |
| Q2 2021 | 37.00% |
| Q1 2021 | 39.44% |
| Q4 2020 | -80.59% |
| Q3 2020 | 91.99% |
| Q2 2020 | -35.46% |
| Q1 2020 | -11.25% |
| Q4 2019 | 11.77% |
| Q3 2019 | -30.15% |
| Q2 2019 | -40.69% |
| Q1 2019 | -48.51% |
| Q4 2018 | 52475.00% |
| Q3 2018 | 11.11% |
| Q2 2018 | -35.71% |
| Q1 2018 | -90.00% |
| Q4 2017 | -35.48% |
| Q3 2017 | -2.25% |
| Q2 2017 | 19.35% |
| Q1 2017 | -64.33% |
| Q4 2016 | -10.78% |
| Q3 2016 | 2.90% |
| Q2 2016 | -9.70% |
| Q1 2016 | -36.37% |